{"title":"克服晚期子宫内膜癌的疾病进展：序贯治疗的临床病例。","authors":"Amedeo Cefaliello, Angela Grieco, Roberto Buonaiuto, Valeria Forestieri","doi":"10.7573/dic.2025-4-5","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy has revolutionized the treatment landscape for solid tumours. Here, we describe the case of a 69-year-old woman with advanced endometrial cancer (EC) who achieved prolonged disease control with immunotherapy. The patient was diagnosed with stage IIIC EC in February 2020 and was treated with carboplatin and paclitaxel, followed by radiotherapy. Relapses occurred in February 2021 (treated with doxorubicin and palliative radiotherapy) and July 2022 (treated with a carboplatin rechallenge). Pembrolizumab and lenvatinib were started in November 2022. Although the initial scan showed progressive disease, restaging 2 months later showed stable disease, which was maintained on pembrolizumab and lenvatinib until progression in October 2024. This article is part of the <i>New treatment options for advanced endometrial carcinoma</i> Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221136/pdf/","citationCount":"0","resultStr":"{\"title\":\"Overcoming disease progression in advanced endometrial cancer: a clinical case of sequential therapies.\",\"authors\":\"Amedeo Cefaliello, Angela Grieco, Roberto Buonaiuto, Valeria Forestieri\",\"doi\":\"10.7573/dic.2025-4-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Immunotherapy has revolutionized the treatment landscape for solid tumours. Here, we describe the case of a 69-year-old woman with advanced endometrial cancer (EC) who achieved prolonged disease control with immunotherapy. The patient was diagnosed with stage IIIC EC in February 2020 and was treated with carboplatin and paclitaxel, followed by radiotherapy. Relapses occurred in February 2021 (treated with doxorubicin and palliative radiotherapy) and July 2022 (treated with a carboplatin rechallenge). Pembrolizumab and lenvatinib were started in November 2022. Although the initial scan showed progressive disease, restaging 2 months later showed stable disease, which was maintained on pembrolizumab and lenvatinib until progression in October 2024. This article is part of the <i>New treatment options for advanced endometrial carcinoma</i> Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.</p>\",\"PeriodicalId\":11362,\"journal\":{\"name\":\"Drugs in Context\",\"volume\":\"14 \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221136/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in Context\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7573/dic.2025-4-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2025-4-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Overcoming disease progression in advanced endometrial cancer: a clinical case of sequential therapies.
Immunotherapy has revolutionized the treatment landscape for solid tumours. Here, we describe the case of a 69-year-old woman with advanced endometrial cancer (EC) who achieved prolonged disease control with immunotherapy. The patient was diagnosed with stage IIIC EC in February 2020 and was treated with carboplatin and paclitaxel, followed by radiotherapy. Relapses occurred in February 2021 (treated with doxorubicin and palliative radiotherapy) and July 2022 (treated with a carboplatin rechallenge). Pembrolizumab and lenvatinib were started in November 2022. Although the initial scan showed progressive disease, restaging 2 months later showed stable disease, which was maintained on pembrolizumab and lenvatinib until progression in October 2024. This article is part of the New treatment options for advanced endometrial carcinoma Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.
期刊介绍：
Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
